1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

30 Dec 2022
Admin
News Article

Us Fda Approves Tg Therapeutics Multiple Sclerosis Drug

The Drug, Ublituximab, To Be Branded As Briumvi, Is The Third From Its Class To Be Approved By The Food And Drug Administration For The Treatment Of Relapsing Multiple Sclerosis After Roche'S Ocrevus And Novartis Ag'S Kesimpta.The Us Health Regulator On Wednesday Approved Tg Therapeutics Inc'S Drug For Patients With Relapsing Forms Of Multiple Sclerosis, Pitting It Against Rivals From Roche And Novartis. The New York-Based Company'S Shares Rose Nearly 9 Per Cent In Afternoon Trade. Tg Therapeutics Did Not Immediately Respond To A Reuters Request For Details On The Pricing And Availability Of The Drug. The Drug, Ublituximab, To Be Branded As Briumvi, Is The Third From Its Class To Be Approved By The Food And Drug Administration For The Treatment Of Relapsing Multiple Sclerosis After Roche'S Ocrevus And Novartis Ag'S Kesimpta. At Least Two Analysts Ahead Of The Approval Had Expected Briumvi To Cost Less Than Existing Drugs In The Same Class Of Treatments, Which Are Priced Between $65,000 And $83,000 Annually. The Approval Of Tg'S First Commercial Product Comes At A Time When The Company Announced Cost-Cut Plans Following The Withdrawal Of Its Lymphatic Cancer Drug Earlier This Year

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!